Lexicon Pharmaceuticals Inc
F:LX31
Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
Pipeline focus: Lexicon is advancing three late-stage programs—sotagliflozin (cardiometabolic/HCM/T1D), pilavapadin (diabetic peripheral neuropathic pain), and LX9851 (obesity via Novo Nordisk)—and highlighted multiple near-term catalysts in 2026.
SOTAGLIFLOZIN HCM: SONATA-HCM is >50% enrolled with completion expected mid-2026 and top-line results targeted in Q1 2027.
Zynquista (T1D): FDA confirmed STENO1 trial data could support an NDA resubmission; company expects to resubmit in 2026 with a ~6-month review and potential approval later in 2026.
Pilavapadin path: Successful end-of-Phase II meeting with FDA (no objections to Phase III); Phase III design agreed (two 12-week placebo-controlled studies) and Lexicon is seeking a development partner rather than fully self-funding pivotal trials.
Finance / cost discipline: Q4 revenue $5.5M and FY revenue $49.8M; meaningful operating expense reductions year-over-year and a strengthened cash position with >$100M raised after year-end.
Novo Nordisk collaboration: LX9851 triggered a $10.0M milestone in February and has potential for an additional $20.0M in 2026.
2026 expense guidance: Total operating expenses expected $100.0M–$110.0M; R&D $63.0M–$68.0M; SG&A $37.0M–$42.0M.
